It is also crucial to recognize that the presence of PD-L1 expression does not universally predict a favourable response to immune checkpoint inhibitors, as some PD-L1-negative tumours may nonetheless derive benefit from such therapies (1). This evidence concerns the gene CD274 and neoplasm.